Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Denosumab (Prolia) Clear all
Completed Phase 2 Interventional Results available

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02470091
View directory record Official record
Conditions
Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7
Interventions
Denosumab, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
11 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
132
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

NCT01753856
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Denosumab, Demeclocycline, Tetracycline, Calcium Supplement, Vitamin D
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Lakewood, Colorado • Gainesville, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 22, 2026, 9:40 AM EDT
Terminated Phase 4 Interventional

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

NCT03029442
View directory record Official record
Conditions
Secondary Osteoporosis, Spinal Cord Injury
Interventions
Denosumab (Prolia), Placebo (normal saline)
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 22, 2026, 9:40 AM EDT
Terminated Phase 4 Interventional Results available

Denosumab in Primary Hyperparathyroidism

NCT01558115
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

NCT00896454
View directory record Official record
Conditions
Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Metastatic Cancer, Multiple Myeloma, Parathyroid Neoplasms, Renal Cancer, Thyroid Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer
Interventions
denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Encinitas, California • New Haven, Connecticut • Salisbury, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 22, 2026, 9:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459
View directory record Official record
Conditions
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions
Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

NCT02157948
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Denosumab (CP2), Denosumab (CP4)
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 100 Years · Female only
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Santa Maria, California • South Lake Tahoe, California • Lakewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

NCT04907539
View directory record Official record
Conditions
Colorectal Cancer
Interventions
RXC004, Nivolumab, Denosumab
Drug · Biological
Lead sponsor
Redx Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

NCT02053753
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Denosumab CP4, Denosumab CP2
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380
View directory record Official record
Conditions
Osteoporosis
Interventions
denosumab, teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 22, 2026, 9:40 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

NCT02130973
View directory record Official record
Conditions
Osteoporosis
Interventions
Standard Clinical Practice Regimen, Experimental Cyclic Regimen
Drug
Lead sponsor
Health Research, Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 22, 2026, 9:40 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

NCT04711109
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions
Denosumab, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 22, 2026, 9:40 AM EDT
Recruiting No phase listed Observational

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

NCT05590949
View directory record Official record
Conditions
Breast Cancer
Interventions
Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score
Other · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 22, 2026, 9:40 AM EDT
Active, not recruiting Phase 4 Interventional

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

NCT05101018
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injuries
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

NCT03396315
View directory record Official record
Conditions
IOP, Osteoporosis
Interventions
Alendronate, Zoledronic Acid
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 22, 2026, 9:40 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Markers of Osteoporosis in Cystic Fibrosis

NCT03921060
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Denosumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 22, 2026, 9:40 AM EDT
Not listed Phase 4 Interventional

Denosumab Administration After Spinal Cord Injury

NCT01983475
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injury
Interventions
Denosumab, Placebo (identical Denosumab volume of normal saline)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 22, 2026, 9:40 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Results available

Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study

NCT04177940
View directory record Official record
Conditions
Osteoporosis
Interventions
DMAB Discontinuation and Switching
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

NCT05087030
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
RGB-14-P, Prolia®
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 22, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

NCT01575873
View directory record Official record
Conditions
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Interventions
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 22, 2026, 9:40 AM EDT
Terminated Early Phase 1 Interventional Results available

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

NCT03382574
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Denosumab, Salpingo-Oophorectomy
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 22, 2026, 9:40 AM EDT
Completed No phase listed Observational Results available

Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

NCT02732210
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Female only
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
60
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 22, 2026, 9:40 AM EDT